Kelly Education hosts substitute teacher pre-hiring event in River Market
KANSAS CITY, Mo. — You have a chance to start a new career and help local kids at the same time.
Kelly Education is hosting a substitute teacher pre-hire event at its office in the River Market.
Why Missouri lawmakers can challenge voter-approved laws
is the nation's largest provider of educators.
Wednesday's pre-hire event benefits Kansas City area schools. A team of recruiters and onboarders are there to answer questions and guide candidates through the hiring process.
You don't need a college degree to be a substitute teacher, but you do need at least 36 college credit hours or a willingness to get certified.
Kelly Education will provide all the training you need for free to become a substitute teacher.
'I think sometimes, especially when we get to this time of year, I think people look at substitute teaching and think hey, it's probably not the time to start substitute teaching, but we recruit year around, because our schools not only have to finish the school year this year, but they have summer school we have to work through,' said Keith Elliott, director of client services at Kelly Education.
If you're interested in becoming a substitute teacher, head to Kelly Education in the River Market at 105 E. 5th Street.
FOX4 Newsletters: Sign up for daily forecasts and Joe's Weather Blog in your inbox
The pre-hire event is also Thursday from 9 a.m. to 3 p.m. Walk-ins are welcome. If you are unable to attend the event you can .
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
12 minutes ago
- Yahoo
Metsera Unveils First-in-Class Once-Monthly Amylin Candidate MET-233i's Positive Phase 1 Results
Metsera, Inc. (NASDAQ:MTSR) is one of the 13 Biotech Stocks with Huge Upside Potential. Metsera, Inc. (NASDAQ:MTSR) reported encouraging Phase 1 results for MET-233i, its once-monthly amylin analog, which showed a mean weight loss of up to 8.4% at Day 36 after subtracting the placebo. A laboratory technician researching a sample of cells in a biotechnology laboratory. The candidate supported monthly dosing with the longest half-life of any known amylin analog, 19 days. MET-233i had no safety indications and was well tolerated. The trial included 80 overweight or obese participants, with individual cases resulting in weight loss of up to 10.2%. MET-233i displayed high tolerability and dose-linear pharmacokinetics when tested in both single and multiple ascending dose formats. The majority of adverse gastrointestinal events occurred in the first week and were mild and dose-dependent. According to preliminary findings, it might make it practical to use its fully-biased GLP-1 RA candidate, MET-097i, in the first monthly GLP-1 + amylin combination therapy. Topline results from combination trials and an ongoing monotherapy study with MET-097i are anticipated in late 2025. Metsera, Inc. (NASDAQ:MTSR)'s HALO™ peptide stabilization platform supports the program. Metsera, Inc. (NASDAQ:MTSR) is a clinical-stage biopharmaceutical business focused on developing new treatments for obesity and metabolic diseases. It is one of the stocks with the biggest upside. While we acknowledge the potential of MTSR as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 High-Growth EV Stocks to Invest In and 13 Best Car Stocks to Buy in 2025. Disclosure. None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
36 minutes ago
- Yahoo
‘Global arms race with artificial intelligence': TN rep. supports xAI project moving forward
MEMPHIS, Tenn. — A state representative from Memphis says he supports Elon Musk's xAI, and says the company is planning up to eight more sites in the area. Republican state Rep. John Gillespie's comments came after state representatives had a press conference on Tuesday against the project moving forward. 'Why is economic development always at the cost of poor folk? Always at the cost of low wel people? We as a city have to have higher self-esteem, we as a city have to believe better about who we are,' said State Rep. Justin J. Pearson, (D-Memphis). Pearson and other democratic lawmakers met with Memphis Mayor Paul Young on Tuesday. Republican Rep. John Gillespie (R-Memphis) says he was there too, and he has a different take on xAI. Memphis mayor meets with state leaders over xAI concerns 'I'm extremely excited and the potential of all the other things that will follow,' said Gillespie. 'We're in a global arms race with artificial intelligence.' 'We're competing not with Silicon Valley, but we're actually competing with China and Russia, and North Korea. xAI and people at xAI have said that they plan on winning that arms race,' said Gillespie. In a statement, he talked about the large amount of tax dollars the company brings also saying, 'Hundreds of Memphians are currently working in construction as xAI plans to build on at least eight sites in Shelby County. ' Rep. Justin Pearson, NAACP aim to halt xAI project in Memphis 'Right now if you do look up, xAI has four sites right now that they have and they've publicly said more are to come. I don't know how many that number is, I hope it's more than eight but I suspect it will be more than eight as well,' said Gillespie. 'Well the data that I've seen and the health department has confirmed and the manufacturer of the turbines have also confirmed, they have technology on there that makes it no more than a dry cleaning or a gas station,' said Gillespie. Mayor Paul Young said there are plans to bring more community-based testing of the air quality in the area of xAI. 'My goal is to make sure our people are protected from a health perspective and that we use this project to boost our city economically,' said Mayor Young. Gillespie says he's all for the testing. It's unclear when that testing will be happening in southwest Memphis and the Boxtown community. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
43 minutes ago
- Yahoo
RadNet Secures $100 Million Incremental Term Loan to Fund Acquisitions and Corporate Initiatives
LOS ANGELES, June 11, 2025 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT) ('RadNet'), a national leader in providing high-quality, cost-effective, fixed-site outpatient diagnostic imaging services, today announced that it has entered into Incremental Amendment No. 2 (the 'Second Amendment') to its Third Amended and Restated First Lien Credit and Guaranty Agreement, as amended (the 'Existing Credit Agreement' and, as amended by the Second Amendment, the 'Credit Agreement'). Pursuant to the Second Amendment, Barclays Bank PLC, as lender, committed to provide RadNet an incremental term loan in the aggregate principal amount of $100.0 million (the '2025 Incremental Term Loan'), which will be added to and form a part of the existing term loan under the Existing Credit Agreement (the 'Existing Term Loan,' together with the 2025 Incremental Term Loan, the 'Term Loan'). The 2025 Incremental Term Loan will mature on April 18, 2031—coincident with the maturity date of the $868.4 million balance of the Existing Term Loan under the Existing Credit Agreement. Quarterly payments of principal on the Term Loan will be approximately $2.4 million compared to approximately $2.2 million prior to the entry of the Second Amendment. All other terms and covenants of the Credit Agreement (as amended by the Second Amendment) remain unchanged. The proceeds of the 2025 Incremental Term Loan will be used to finance future acquisitions and for other general corporate purposes, providing RadNet with additional flexibility to pursue strategic growth opportunities across its national imaging center network and technology platforms. Mark Stolper, Executive Vice President and Chief Financial Officer of RadNet, commented, 'We appreciate the continued support of Barclays and our relationship banks and term-loan lenders. This incremental financing increases our capacity to execute on a pipeline of acquisition opportunities while maintaining our conservative capital structure. The proceeds of approximately $100 million adds to the $717 million cash balance as of March 31, 2025, positioning us to advance our growth strategy and create long-term value for our stockholders.'RadNet, Inc. is a leading national provider of freestanding, fixed-site diagnostic imaging services in the United States based on the number of locations and annual imaging revenue. RadNet has a network of 401 owned and/or operated outpatient imaging centers. RadNet's imaging center markets include Arizona, California, Delaware, Florida, Maryland, New Jersey, New York and Texas. In addition, RadNet provides radiology information technology and artificial intelligence solutions marketed under the DeepHealth brand, teleradiology professional services and other related products and services to customers in the diagnostic imaging industry. Together with contracted radiologists, and inclusive of full-time and per diem employees and technologists, RadNet has a total of over 11,000 employees. For more information, visit
